公开(公告)号：US20250136941A1

公开(公告)日：2025-05-01

申请号：US18835270

申请日：2023-02-27

Applicant: KATAOKA CORPORATION ,  Kyoto Prefectural Public University Corporation

Inventor： Ping DAI ,  Yoshinori HARADA ,  Toshihiro KURAHASHI ,  Hiroko NAMBA ,  Junichi MATSUMOTO

IPC: C12N5/077

Abstract: The present disclosure provides a method for producing growth factor-producing cells by inducing differentiation directly from somatic cells, and a composition for producing growth factor-producing cells by inducing differentiation directly from somatic cells.

公开(公告)号：US20240385177A1

公开(公告)日：2024-11-21

申请号：US18692497

申请日：2022-09-15

Applicant: KATAOKA CORPORATION ,  Kyoto Prefectural Public University Corporation

Inventor： Ping DAI ,  Yukimasa TAKEDA ,  Yoshinori HARADA ,  Junichi MATSUMOTO

IPC: G01N33/50 ,  C12N5/00 ,  C12N5/077

Abstract: The present disclosure relates to a new screening method to search for compounds that have browning-promoting or browning-inhibiting effects on brown adipocytes and that target cell membrane receptors.

公开(公告)号：US20240165407A1

公开(公告)日：2024-05-23

申请号：US18284086

申请日：2022-03-24

Applicant: Kyoto Prefectural Public University Corporation

Inventor： Osamu Ukimura ,  Yasuyuki Naito

IPC: A61N1/36 ,  A61N1/04

CPC classification number: A61N1/36007 ,  A61N1/0484 ,  A61N1/36034

Abstract: A urinary incontinence treatment device includes: a sensor for detecting urination; stimulation pads configured to apply a stimulus to a wearer; and a mechanical member including a stimulus generation unit for generating a signal for causing the stimulation pads to apply the stimulus to the wearer and a control unit for controlling the stimulus generation unit to generate the signal in response to urination detection by the sensor. The stimulation pads include a first pair of stimulation pads and a second pair of stimulation pads. The stimulus generation unit supplies electrical signals having different frequencies. The first pair of stimulation pads and the second pair of stimulation pads are arranged such that an electrical signal applied from the first pair of stimulation pads and an electrical signal applied from the second pair of stimulation pads intersect each other in the wearer's body and a resulting interference wave reaches the bladder.

公开(公告)号：US11851681B2

公开(公告)日：2023-12-26

申请号：US15769595

申请日：2016-10-20

Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION

Inventor： Kenta Yamamoto ,  Tsunao Kishida ,  Yoshihiro Sowa ,  Toshiro Yamamoto ,  Osam Mazda

IPC: C12N5/077 ,  C12N5/0775

CPC classification number: C12N5/0656 ,  C12N5/0653 ,  C12N5/0654 ,  C12N5/0655 ,  C12N5/0658 ,  C12N5/0663 ,  C12N2501/15

Abstract: Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-β pathway inhibitor.

公开(公告)号：US20230380417A1

公开(公告)日：2023-11-30

申请号：US18032726

申请日：2021-10-19

Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION

Inventor： Shigeru KINOSHITA ,  Munetoyo TODA ,  Chie SOTOZONO ,  Morio UENO

IPC: A01N1/02 ,  C12N5/079 ,  A61K35/30

CPC classification number: A01N1/0284 ,  C12N5/0621 ,  A61K35/30 ,  A01N1/0226 ,  C12N2501/11 ,  C12N2501/70

Abstract: Human corneal endothelial cells and/or human corneal endothelial precursor cells are preserved with a high survival rate of these cells being maintained, and the occurrence rate of contaminated cells in post-preservation culturing is suppressed. A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells is characterized in that human corneal endothelial cells and/or human corneal endothelial precursor cells that have been cultured using a culture medium that contains a ROCK inhibitor, and in which the content of epidermal growth factor (EGF) is less than a concentration that will cause a transformation are harvested at a timing when any one of or a plurality of the conditions (a)˜(d) have been met, and are placed in a suspension state and then preserved.

公开(公告)号：US11826244B2

公开(公告)日：2023-11-28

申请号：US16485264

申请日：2018-02-13

Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION

Inventor： Kentaro Kojima

IPC: A61F2/16

CPC classification number: A61F2/16 ,  A61F2/1662 ,  A61F2002/169 ,  A61F2002/16901 ,  A61F2002/16902 ,  A61F2002/169053 ,  A61F2220/0025 ,  A61F2230/0006 ,  A61F2230/0008

Abstract: Provided is an intraocular lens affixing device which makes it possible to affix an intraocular lens of any kind with respect to the inside of an eye with a ruptured or deleted lens capsule. The intraocular lens affixing device 1 is provided with a device support portion (A) and an intraocular lens housing portion (B) connected to the device support portion (A). The device support portion (A) includes a frame 2 having a shape matching a ciliary sulcus 36. Also provided is an affixing kit for inserting an intraocular lens, the kit being provided with a) an intraocular lens affixing device; and b) an injector for injecting the affixing device.

公开(公告)号：US20230082555A1

公开(公告)日：2023-03-16

申请号：US17779639

申请日：2020-11-18

Applicant: Kataoka Corporation ,  Kyoto Prefectural Public University Corporation

Inventor： Ping Dai ,  Yukimasa Takeda ,  Yoshinori Harada ,  Junichi Matsumoto

IPC: C12N5/077

Abstract: The present invention is primarily directed to provide a new composition for a medium which can be used for differentiation induction from somatic cells to brown adipocytes.
The present invention can include, for example, a composition for a medium used in differentiation induction from somatic cells to brown adipocytes, wherein the composition comprises the following seven components: a thyroid hormone receptor agonist, a glucocorticoid receptor agonist, a phosphodiesterase inhibitor, insulin, an ascorbic acid derivative, albumin, and an antibiotic.
According to the present invention, direct differentiation induction from somatic cells to brown adipocytes can be effectively performed. In addition, according to the present invention, it is possible to effectively maintain brown adipocytes.

公开(公告)号：US20230059404A1

公开(公告)日：2023-02-23

申请号：US17779567

申请日：2020-11-18

Applicant: Kataoka Corporation ,  Kyoto Prefectural Public University Corporation

Inventor： Ping Dai ,  Yukimasa Takeda ,  Yoshinori Harada ,  Junichi Matsumoto

IPC: A61K35/35 ,  C12N5/077

Abstract: The present invention is primarily directed to provide a new process capable of performing direct conversion of or induction from a somatic cell to brown adipocytes with low molecular weight compounds, without performing artificial gene transfer.
The present invention includes, for example, a process for producing brown adipocytes by direct differentiation induction from somatic cells, comprising a step of culturing a somatic cell in a serum-free differentiation induction medium in the presence of a selective PPARγ agonist and a cAMP inducer.
According to the present invention, direct conversion of or induction from somatic cells to brown adipocytes can be effectively performed without gene transfer. The brown adipocytes obtained by the present invention are useful as regenerative medicine, models of human brown adipocytes and human beige cells, and the like.

公开(公告)号：US20220296580A1

公开(公告)日：2022-09-22

申请号：US17831843

申请日：2022-06-03

Applicant: Kyoto Prefectural Public University Corporation ,  The Doshisha ,  Senju Pharmaceutical Co., Ltd.

Inventor： Noriko KOIZUMI ,  Naoki OKUMURA ,  Shigeru KINOSHITA

IPC: A61K31/4439 ,  A61K9/00 ,  A61K31/437 ,  A61K31/444 ,  C07K16/22 ,  A61K31/519 ,  A61K31/713 ,  A61K38/00 ,  A61K39/395 ,  A61K31/4709

Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

公开(公告)号：US20220265714A1

公开(公告)日：2022-08-25

申请号：US17626345

申请日：2020-07-30

Applicant: SHINSHU UNIVERSITY ,  KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  BrightPath Biotherapeutics Co., Ltd.

Inventor： Yozo Nakazawa ,  Shigeki YAGYU ,  Miyuki TANAKA ,  Kayoko NAKAMURA ,  Masahiro OKADA ,  Makoto KONDO ,  Tomokuni SHIGEURA ,  Shogo HIROTA

IPC: A61K35/17 ,  C12N5/0783 ,  A61P35/00 ,  C07K14/715 ,  C07K14/705 ,  C07K16/32

Abstract: The present disclosure includes a method of producing a cell population containing Chimeric Antigen Receptor (CAR)-expressing immune cells, comprising co-culturing CAR-expressing immune cells and cells expressing a target antigen of the CAR, wherein the CAR-expressing immune cells are cells into which a CAR gene has been introduced and the target antigen-expressing cells are normal blood cells that have been engineered to express the target antigen.